Autoinjectors: A Revolutionary Leap in Drug Delivery

In recent years, the biopharmaceutical industry has experienced a paradigm shift with the increasing prominence of autoinjectors. In 2023, the global autoinjector market size was USD 9.34 billion and is expected to grow at a CAGR of 16.05% to USD 19.67 billion by 2028.1

This rapid growth is driven by the increasing adoption of self-administration devices across various therapeutic areas for allergies and lifestyle and chronic diseases such as psoriasis, diabetes, multiple sclerosis, and rheumatoid arthritis. Biopharmaceutical companies are actively incorporating autoinjector drug delivery technology into their product portfolios, recognizing the competitive advantage these devices offer in terms of differentiation and patient satisfaction. As a result, the autoinjector market is witnessing a surge in innovation, with companies investing in research and development to enhance device features and compatibility with a diverse range of biologic drug products.

These user-friendly drug-device combination products have revolutionized drug delivery, offering patient’s greater convenience, accuracy, and control over their treatment regimens. As the demand for biologic therapies continues to grow, autoinjectors are emerging as a key drug delivery mechanism in enhancing patient adherence, reducing healthcare costs, and improving overall treatment outcomes.

Benefits of autoinjectors

1. Precision in drug delivery: autoinjectors are designed to administer precise doses of biologic drug products, ensuring accurate and consistent delivery. By automating the injection process, autoinjectors minimize the risk of human error, providing a level of accuracy that is paramount in the treatment of complex conditions such as autoimmune disorders and chronic diseases.

2. Safety and reduced risk of contamination: autoinjectors are designed to minimize the risk of contamination and infection associated with traditional methods of drug administration such as vials and syringes. The sealed, prefilled cartridges or syringes used in autoinjectors protect the medication from external contaminants, ensuring the integrity of the drug product. Additionally, the automated injection process reduces the likelihood of accidental needle stick injuries, enhancing safety for both patients and healthcare providers.

3. Patient-Centric Approach: The surge in autoinjector usage can be attributed to the growing emphasis on patient-centric healthcare. These devices empower patients to self-administer medications in the comfort of their homes, eliminating the need for frequent hospital visits. The user-friendly design of autoinjectors, often featuring intuitive interfaces and ergonomic grips, enhances patient compliance and reduces anxiety associated with traditional injection methods. This change towards at-home administration not only improves patients’ quality of life but also reduces the burden on healthcare infrastructure.

Market Expansion and Technological Advancements

The global autoinjector market has experienced remarkable growth, driven by continuous technological advancements and collaborations between pharmaceutical companies, device manufacturers and partnering Contract Development and Manufacturing Organizations (CDMOs). Companies are investing in research and development to enhance the capabilities of autoinjectors, including features such as connectivity for real-time monitoring and dose tracking. The expanding market is also witnessing the integration of smart devices and data-driven solutions, further optimizing patient care and treatment outcomes.

Advanced Drug Delivery Solutions at PCI Pharma Services

With the pharmaceutical industry’s growing pipeline of biologics, the need for technically advanced sterile manufacturing and specialized advanced drug delivery packaging support has grown considerably. Committed to being a market leader in the packaging of biologic drug products for our global clients, our goal is to support our customers in safely, and efficiently bringing their novel therapies to patients.

Driven by innovation and patient-centricity, our design and development expertise combined with our device assembly and advanced drug delivery packaging capabilities offer flexible solutions for a diverse portfolio of conventional and specialty injectable drug-device combination products. We have the scalability to handle the dynamic volumes of biopharmaceutical therapies, whether large or small, from niche personalized medicines to large-volume treatments.

Expert advice from device strategy to packaging design

With a global network of experts with experience in advanced drug delivery, PCI can provide guidance at critical time points to assist you developing an optimum patient-centric drug-device combination product.

Our deep industry experience can help determine the best device strategy for your patient and drug product, from the use of established well-accepted platforms that have received regulatory approval as part of a drug-device combination product, which may be deemed lower risk for a new program, or alternatively, a more innovative device approach which may be deemed more attractive for specific patient populations compared to that of more traditional and readily available platforms.

PCI’s pharmaceutical packaging design department provides an innovative and value-added service. Our dedicated team of in-house design specialists deliver insightful packaging design and practical knowledge to deliver differentiated and cost-effective packaging solutions. Working with our client partners as early as possible during their drug products clinical phases, our design department together with a cross functional network of experts in sterile drug product manufacturing, engineering, operations and approved vendors develop expert design processes focused on human factors engineering and technical functionality and deliver optimized designs for manufacturability, scalability and automation. This seamless solution ensures that key considerations are addressed at the right time, leading to both cost and time efficiencies and ultimately ensuring speed to market.

Expanding our drug-device combination capabilities and capacities

Complementing the continued growth and investment across our sterile manufacturing network, we continue to expand our European, North American and UK Centers of Excellence for clinical and commercial packaging. These state-of-the-art facilities are equipped with advanced drug delivery packaging technologies for the assembly and labeling of vials, cartridges, standard prefilled syringes, advanced safety syringes, autoinjector and pen devices complete with integrated top-load cartoning and in-line serialization.

Most recently, we announced an investment of $150M in a new 200,000 sq ft facility at our Rockford,IL, site to meet the growing biologic market need of specialized packaging for injectable drug-device combination products. With over 20 dedicated suites, the new facility will support the assembly and packaging of vials, prefilled syringes, autoinjectors, on-body injectors and pen-cartridges such as those for glucagon-like peptide 1 agonists (GLP-1) for treatment of diabetes and obesity as well as those needed for oncology treatment and autoimmune diseases.

Flexible, scalable autoinjector assembly

As a global leading CDMO, PCI provides highly flexible, reliable, advanced drug delivery packaging solutions to meet the dynamic needs of our clients. Meeting the exponential growth in the development and use of autoinjectors, PCI continues to invest in innovative scalable autoinjector assembly and labeling technologies.
Although many autoinjector devices have similar components, their design varies in terms of size, material and shape. With true customer focus and flexibility at the core of our injectable packaging service offering, our technologies can adapt to the unique requirements of each global market from concept to commercialization.
For example, our specialized clinical and low-volume commercial autoinjector assembly line provides a multi-platform autoinjector solution including Ypsomed Ypsomate, SHL Molly, and Becton Dickson (BD) Physioject alongside other platform devices. It also has the capability to assemble and label needle safety device platforms such as BD Ultrasafe/Plus and Nemera Safe & Sound making it the ideal technology for development studies, clinical trials and niche orphan drugs.

Providing an integrated scalable solution, our mid-high volume commercial assembly technologies are also able to accommodate various autoinjectors types from different manufacturers at a larger scale for product launch and commercial market supply. Supporting true customization, the RDA can easily and cost-effectively be retooled for future new autoinjector types allowing us to respond quickly and efficiently to technological changes and future innovation.

Seamless Solutions

At PCI, ensuring life-changing medicines reach those who need it most is our highest priority. As a truly integrated global CDMO, we are manufacturing, packaging and supply chain experts, harnessing our experience and expertise to deliver seamless solutions with the ultimate aim of improving the lives of patients. Providing expert sterile fill-finish and lyophilization solutions from development to commercialization together with integrated custom packaging solutions for sterile injectables allows for ultimate knowledge sharing and communication between teams to ensure the drug product packaging is optimized for the product, patient and production.
With in-house laboratories we provide a range of packaging and analytical services to support client’s development, clinical and commercial supply of medicines globally. From product ID testing, method transfer, release and stability testing to autoinjector system testing with functional tests such as cap removal force, activation force, extended needle length, dose accuracy, injection time, lockout force, we ensure your life-changing therapy meets regulatory guidelines and is safe for patient use.

Conclusion

The widespread adoption of autoinjectors represents a transformative leap in the biopharmaceutical industry’s approach to drug delivery. These devices offer a compelling solution to the challenges of precise dosing, patient adherence, and safety, particularly in the context of the rising prominence of biologics. As technology continues to advance and regulatory frameworks evolve, autoinjectors are poised to play an increasingly integral role in shaping the future of drug administration, offering patients a more accessible, convenient, and personalized healthcare experience.

As a leading global CDMO, as part of our strategy to support advanced drug delivery for novel molecules, PCI’s integrated sterile drug manufacturing and injectable packaging solutions supports our client partners in optimizing dosing and providing convenient, easy to use, patient-centric therapies to patients. We not only want to meet growing demand for scalable sterile manufacturing and advanced drug delivery packaging, but through innovative value add solutions we aim to exceed our customer expectations, delivering flexibility and excellence in all that we do to accelerate the development and commercialization of life-changing therapies.

1. https://www.mordorintelligence.com/industry-reports/autoinjectors-market

Autoinjectors: A Revolutionary Leap in Drug Delivery with Bill Welch, Executive Director of Services at PCI Pharma Services | As seen in International Pharmaceutical Industry | Winter Edition 2023.


We are committed to supporting clients at every stage of the manufacturing cycle, delivering best-in-class services efficiently and effectively.

Find out more about our Advanced Drug Delivery Solutions.


Our dedicated team of specialists will be happy to discuss any of your Autoinjector questions. Contact us on +1 779-208-1819 (US) or +44 1495 711 222 (UK/EU) or email talkfuture@pci.com